Modulation of granzyme k activity in the treatment of skin conditions
AssigneeThe University of British Columbia
InventorsDavid J. GRANVILLE, Christopher TURNER, Matthew ZEGLINSKI, Katlyn RICHARDSON, Sho HIROYASU
Life of this patent
Estimating the term…
Abstract
Methods for treating inflammatory skin conditions, such as atopic dermatitis and psoriasis, and for promoting skin wound healing and for treating skin wounds, such as thermal and pressure injury, by reducing the activity of Granzyme K.
Claims33
A method of treating an inflammatory skin condition in a subject, comprising reducing the activity of Granzyme K in a subject, thereby treating the inflammatory skin condition.
A method of treating a wound in a subject, comprising reducing the activity of Granzyme K in a subject, thereby treating the wound.
A method of treating an inflammatory skin condition in a subject, comprising administering an effective amount of a Granzyme K inhibitor to the subject, thereby treating the inflammatory skin condition.
A method of treating a wound in a subject, comprising administering an effective amount of a Granzyme K inhibitor to the subject, thereby treating the wound.
A method of promoting wound healing in a subject, comprising inhibiting cleavage of syndecan-1 in keratinocytes by reducing the activity of Granzyme K in the subject.
A method of promoting wound healing in a subject, comprising reducing pro-inflammatory cytokine response in keratinocytes, fibroblasts, macrophages, and/or endothelial cells by reducing the activity of Granzyme K in the subject.
A method for promoting wound re-epithelization, comprising reducing the activity of Granzyme K in keratinocytes proximate to the wound.
A method of promoting wound healing in a subject, comprising inhibiting cleavage of syndecan-1 by administering an effective amount of Granzyme K inhibitor to the subject.
A method of promoting wound healing in a subject, comprising reducing pro-inflammatory cytokine response in keratinocytes, fibroblasts, macrophages, and/or endothelial cells by administering an effective amount of Granzyme K inhibitor to the subject.
A method for promoting wound re-epithelization in a subject, comprising inhibiting cleavage of syndecan-1 in a keratinocyte by administering an effective amount of Granzyme K inhibitor to the subject.
A method for promoting wound re-epithelization in a subject, comprising administering an effective amount of Granzyme K inhibitor to the subject.
A method of stimulating re-epithelialization, comprising inhibiting syndecan-1 cleavage in the keratinocyte by reducing the activity of GzmK in the wounded or damaged tissue area.
A method of converting a pro-inflammatory phenotype to a pro-healing wound repair phenotype, comprising reducing pro-inflammatory cytokine responses in keratinocytes, fibroblasts, macrophages, and/or endothelial cells by reducing the activity of GzmK in the wounded or damaged tissue area.
A method for screening a candidate compound for its ability to treat an inflammatory skin condition or to promote wound healing, comprising contacting the candidate compound with Granzyme K in vitro, wherein inhibition of Granzyme K activity compared to Granzyme K that has not been contacted with the candidate compound indicates that the candidate compound is a compound that may be useful for the treatment of the inflammatory skin condition or wound.
Dependencies are inferred from the claim text.